Volume 87 Issue 28 | p. 17 | Concentrates
Issue Date: July 13, 2009

Novavax In Vaccine Deal With Rovi

Department: Business
Keywords: Novavax, Rovi Pharmaceuticals, vaccines

Novavax is licensing its recombinant virus-like-particle (VLP) vaccine technology to Madrid-based Rovi Pharmaceuticals for the development of vaccines under an $83 million program sponsored by the Spanish Ministry of Health. Novavax, based in Rockville, Md., says it is also negotiating a broader licensing deal with Rovi under which the Spanish firm will receive exclusive licenses to Novavax' technology to commercialize flu vaccines in Spain and Portugal and nonexclusive licenses for Europe, . . .

To view the rest of this content, please log in with your ACS ID.



 
Chemical & Engineering News
ISSN 0009-2347
Copyright © American Chemical Society